Literature DB >> 17251303

Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.

Hillel Haim1, Israel Steiner, Amos Panet.   

Abstract

Characterization of the neutralizing interaction between antibody and virus is hindered by the nonsynchronized progression of infection in cell cultures. Discrete steps of the viral entry sequence cannot be discerned, and thus, the mode of antibody-mediated interference with virus infectivity remains undefined. Here, we magnetically synchronize the motion and cell attachment of human immunodeficiency virus type 1 (HIV-1) to monitor the progression of neutralization, both in solution and following virus attachment to the cell. By simultaneous transfer of all viral particles from reaction solution with antibody to the cell-bound state, the precise rate of neutralization of cell-free virus could be determined for each antibody. HIV-1 neutralization by both monoclonal and polyclonal antibody preparations followed distinct pseudo-first-order kinetics. For all antibodies, cell types, and HIV-1 strains examined, postattachment interference served a major role in the neutralizing effect. To monitor the progression of postattachment interference, we synchronized the entry process at initiation and measured the escape of cell-bound virus from antibody. We found that different antibodies neutralized the virus over different time frames during the entry phase. Virus was observed to progress through a sequence of shifting sensitivities to different antibodies during entry, suggested here to correlate with the exposure time of the target epitope on receptor-activated viral envelope proteins. Thus, by monitoring the progression of HIV-1 entry under synchronized conditions, we identify a new and significant determinant of antibody neutralization capacity, namely, the time frames for neutralization during the course of the viral entry phase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251303      PMCID: PMC1866073          DOI: 10.1128/JVI.02293-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  Occupancy and mechanism in antibody-mediated neutralization of animal viruses.

Authors:  P J Klasse; Q J Sattentau
Journal:  J Gen Virol       Date:  2002-09       Impact factor: 3.891

2.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.

Authors:  Catherine M Finnegan; Werner Berg; George K Lewis; Anthony L DeVico
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.

Authors:  James M Binley; Charmagne S Cayanan; Cheryl Wiley; Norbert Schülke; William C Olson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

6.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation.

Authors:  Howard E Davis; Matthew Rosinski; Jeffrey R Morgan; Martin L Yarmush
Journal:  Biophys J       Date:  2004-02       Impact factor: 4.033

9.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

10.  HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation.

Authors:  Ruben M Markosyan; Fredric S Cohen; Grigory B Melikyan
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

View more
  11 in total

1.  Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.

Authors:  Lee S O'Neill; Amy M Skinner; Josha A Woodward; Peter Kurre
Journal:  J Gene Med       Date:  2010-05       Impact factor: 4.565

2.  The High Content of Fructose in Human Semen Competitively Inhibits Broad and Potent Antivirals That Target High-Mannose Glycans.

Authors:  Jacklyn Johnson; Manuel G Flores; John Rosa; Changze Han; Alicia M Salvi; Kris A DeMali; Jennifer R Jagnow; Amy Sparks; Hillel Haim
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

3.  Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.

Authors:  Navid Madani; Amy M Princiotto; Connie Zhao; Fatemeh Jahanbakhshsefidi; Max Mertens; Alon Herschhorn; Bruno Melillo; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

4.  Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies.

Authors:  Jonah B Sacha; David I Watkins
Journal:  Nat Protoc       Date:  2010-01-21       Impact factor: 13.491

5.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

6.  Role of gp120 trimerization on HIV binding elucidated with Brownian adhesive dynamics.

Authors:  Andrew D Trister; Daniel A Hammer
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

7.  Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution.

Authors:  Terrence M Dobrowsky; Yan Zhou; Sean X Sun; Robert F Siliciano; Denis Wirtz
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

8.  Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.

Authors:  Lusine Demirkhanyan; Mariana Marin; Wuyuan Lu; Gregory B Melikyan
Journal:  PLoS Pathog       Date:  2013-06-13       Impact factor: 6.823

9.  Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.

Authors:  Hillel Haim; Zhihai Si; Navid Madani; Liping Wang; Joel R Courter; Amy Princiotto; Aemro Kassa; Marciella DeGrace; Kathleen McGee-Estrada; Megan Mefford; Dana Gabuzda; Amos B Smith; Joseph Sodroski
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

10.  Cell-cell transmission of VSV-G pseudotyped lentivector particles.

Authors:  Amy M Skinner; Santhosh Chakkaramakkil Verghese; Peter Kurre
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.